VESSEL: Vascular and hEmatological medicineS using Scalable Editing pLatforms
The team aims to develop treatments for rare genetic diseases of the vasculature. The program will advance non-viral delivery of gene editors to the vasculature alongside in vitro 3D human vascular models and biomarker-based rapid testing strategies. Together, these capabilities are intended to accelerate development and reduce reliance on lengthy animal studies.